UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

23650

7590

05/22/2008

NOVO NORDISK, INC. INTELLECTUAL PROPERTY DEPARTMENT 100 COLLEGE ROAD WEST PRINCETON, NJ 08540

EXAMINER					
KAM, CHIH MIN					
ART UNIT PAPER NUMBER					
1656					

DATE MAILED: 05/22/2008

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853.193	05/11/2001	Greta Van Den Berghe	6296.204-US	5893

TITLE OF INVENTION: METHODS AND PREPARATIONS FOR CURING CLINICALLY ILL PATIENTS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0	\$1740	08/22/2008

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS; This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where ap in m

maintenance fee notifica	itions.	ock 1 for any change of address)	rders and notification of n a) specifying a new corres				domestic mailings of the
CORRENT CORRESPOND	PENCE ADDRESS (NOIC: USE B.	ock 1 for any change of address)	Fee(c) Transmittal Thi	is certif	icate cannot be used for	or any other accompanying at or formal drawing, must
23650	7590 05/22	//2008	nave			of Mailing or Transı	
NOVO NORD INTELLECTUA 100 COLLEGE	AL PROPERTY DE	PARTMENT	I her State addr trans	reby certify that the	is Fee(s) Transmittal is being	deposited with the United class mail in an envelope above, or being facsimile te indicated below.
PRINCETON, I	NJ 08540						(Depositor's name)
							(Signature)
							(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTO	RNEY DOCKET NO.	CONFIRMATION NO.
09/853,193	05/11/2001		Greta Van Den Berghe			6296.204-US	5893
TITLE OF INVENTION	I: METHODS AND PRE	EPARATIONS FOR CUR	ING CLINICALLY ILL P.	ATIENTS			
C . DOT 11 STATE	I are the same of	T		DDDIL DATE LOGIC			
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUI	E FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1440	\$300	\$0 1		\$1740	08/22/2008
EXAM		ART UNIT	CLASS-SUBCLASS				
	HIH MIN	1656	514-003000				
1. Change of correspond CFR 1.363).		,	2. For printing on the part (1) the names of up to			nevs 1	
Change of corresp Address form PTO/S	oondence address (or Cha B/122) attached.	inge of Correspondence	or agents OR, alternativ	ely,		_	
☐ "Fee Address" ind	lication (or "Fee Address	" Indication form	(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is 3				
Number is required	O2 or more recent) attack	ed. Use of a Customer	listed, no name will be	printed.	по пап	ie is 3	
3. ASSIGNEE NAME A	ND RESIDENCE DATA	A TO BE PRINTED ON	THE PATENT (print or typ	oe)			
PLEASE NOTE: Un recordation as set fort	less an assignee is ident th in 37 CFR 3.11. Com	ified below, no assignee pletion of this form is NO	data will appear on the pa T a substitute for filing an	atent. If an assign	ee is ic	lentified below, the do	cument has been filed for
(A) NAME OF ASSI	•		(B) RESIDENCE: (CITY		COUNT	RY)	
Di Lala			·		,.	ar e e	up entity 🖵 Government
Please check the appropr	riate assignee category or	categories (will not be pr	rinted on the patent):	Individual 🖵 Co	orporati	on or other private gro	up entity Government
4a. The following fee(s)	are submitted:	41	o. Payment of Fee(s): (Plea	se first reapply ar	ny prev	iously paid issue fee s	hown above)
☐ Issue Fee☐ Publication Fee (1	No small entity discount	permitted)	A check is enclosed. Payment by credit care	d. Form PTO-2038	is atta	ched.	
*	# of Copies		The Director is hereby overpayment, to Depo				iciency, or credit any
5. Change in Entity Sta	tue (from status indicate	d above)	overpayment, to Depo	SIL ACCOUNT NUMBE	ег	(enclose an	extra copy of this form).
	ns SMALL ENTITY state	· · · · · · · · · · · · · · · · · · ·	☐ b. Applicant is no long	ger claiming SMAl	LL EN	ΓΙΤΥ status. See 37 CF	R 1.27(g)(2).
NOTE: The Issue Fee an interest as shown by the	nd Publication Fee (if req	uired) will not be accepte tes Patent and Trademark	d from anyone other than the	ne applicant; a regi	istered a	attorney or agent; or the	e assignee or other party in
interest us shown by the	records of the omice st	nes I dont and Traceman	· omec.				
Authorized Signature				Date			
Typed or printed name	ne			Registration N	No		
This collection of inform	nation is required by 37 O	CFR 1.311. The information	on is required to obtain or r	etain a benefit by t	he publ	ic which is to file (and	by the USPTO to process)
Box 1450, Alexandria, V	/irginia 22313-1450. DC	e USPTO. Time will vary rden, should be sent to th O NOT SEND FEES OR	1.14. This collection is est depending upon the indivention office e Chief Information Office COMPLETED FORMS TO	idual case. Any co r, U.S. Patent and D THIS ADDRESS	mment Traden S. SENI	s on the amount of tin nark Office, U.S. Depa D TO: Commissioner f	e you require to complete rtment of Commerce, P.O. or Patents, P.O. Box 1450,
Alexandria, Virginia 223	313-1450.						

PTOL-85 (Rev. 08/07) Approved for use through 08/31/2010.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/853,193	05/11/2001	Greta Van Den Berghe	6296.204-US	5893		
23650 75	23650 7590 0 <i>5</i> /22/2008			EXAMINER		
NOVO NORDIS	K, INC.	KAM, CHIH MIN				
	PROPERTY DEPART	CMENT	ART UNIT	PAPER NUMBER		
100 COLLEGE ROAD WEST PRINCETON, NJ 08540		1656 DATE MAILED: 05/22/200	8			

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 (571)-272-4200.

	Application No.	Applicant(s)
	09/853,193	VAN DEN BERGHE, GRETA
Notice of Allowability	Examiner	Art Unit
	CHIH-MIN KAM	1656
The MAILING DATE of this communication appeal All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commit IGHTS. This application is	n this application. If not included unication will be mailed in due course. THIS
1. This communication is responsive to <u>5/6/08</u> .		
2. ☑ The allowed claim(s) is/are <u>32 and 93-106</u> .		
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). 	e been received. e been received in Application	on No
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be subm	IENT of this application. itted. Note the attached EX	AMINER'S AMENDMENT or NOTICE OF
INFORMAL PATENT APPLICATION (PTO-152) which give	es reason(s) why the oath o	r declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") mus		
(a) ☐ including changes required by the Notice of Draftspers		w (PTO-948) attached
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1		
each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT		
Attachment(s)	5 Notice of In	oformal Datant Application
 Notice of References Cited (PTO-892) Dotice of Draftperson's Patent Drawing Review (PTO-948) 		ıformal Patent Application ummary (PTO-413),
 Information Disclosure Statements (PTO/SB/08), 	Paper No.	/Mail Date Amendment/Comment
Paper No./Mail Date <u>5/6/08</u>		
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ☑ Examiner's 9. ☐ Other	Statement of Reasons for Allowance

Application/Control Number: 09/853,193 Page 2

Art Unit: 1656

DETAILED ACTION

1. The Request for Continued Examination (RCE) filed on May 6, 2008 under 37 CFR

1.114 is acknowledged. An action on the RCE follows.

Status of the Claims

2. Claims 32 and 93-106 are pending.

Applicant's amendment filed May 6, 2008 is acknowledged, and applicants' response has been fully considered. New claims 97-106 have been added. Therefore, claims 32 and 93-106 are examined.

The following is an **Examiner's Statement of Reasons for Allowance**: The following reference appears to be the closest art to the claimed invention. Scott et al. (Stroke 30, 793-799 (1999)) teach the use of a 24-hour infusion of saline (for control) or a glucose potassium insulin (GKI) infusion (including 16 U of human soluble insulin, 20 mmole of KCl in 500 ml 10% dextrose) at 100 mL/h in the treatment of 53 acute stroke patients with mild or moderate hyperglycemia (plasma glucose between 7.0 and 17.0 mmole/L, corresponding to 126 and 307 mg/dL) in an explanatory, randomized, controlled trial to test safety of the treatment, where no statistically significant differences is detected between the two groups at baseline (Table 1), and the GKI group had lower mean plasma glucose levels at 8 hours (6.4 mmole/L, corresponding to 115 mg/dL), 16 hours (6.5 mmole/L, corresponding to 117 mg/dL) and 24 hours (6.9 mmole/L, corresponding to 124 mg/dL) from the time starting infusion as compared to control, and the mean plasma glucose level is 9.1 mmole/L (corresponding to 164 mg/dL) at zero time of infusion. The reference also indicates that of the patients in the GKI group, 21 (84 %) received 2400 mL infusate compared with 24 (96%) in the control group (page 795, second column), and the infusions were maintained over next 24 hrs, however, the treatment shows no difference in the mortality rate for GKI and control groups (Table 3). Thus, the reference does not teach a method of treating a critically ill patient or a CIPNP patient by administering an insulin compound, where the treatment reduces the incidence of mortality, the incidence of critical illness polyneuropathy, the incidence of sepsis, the incidence of renal failure, or the incidence of multiple organ failure in the critically ill patients or CIPNP patients. Therefore, the claims are allowable over the art of record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 09/853,193 Page 3

Art Unit: 1656

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chih-Min Kam whose telephone number is (571) 272-0948. The examiner can normally be reached on 8.00-4:30, Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Bragdon can be reached at 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Chih-Min Kam/

Primary Examiner, Art Unit 1656

CMK

May 14, 2008